T. Rowe Price Associates
TNXP icon

T. Rowe Price Associates’s Tonix Pharmaceuticals TNXP Stock Holding History

T. Rowe Price Associates’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
19,363
+5,547
+40% +$71.6K ﹤0.01% 2930
2026
Q1 		$190K Buy
13,816
+2,883
+26% +$44.4K ﹤0.01% 2861
2025
Q4 		$171K Buy
+10,933
New +$202K ﹤0.01% 2846
2022
Q2 		– Hold
0
– -$10K – 3014
2022
Q1 		– Hold
0
– – – 2964
2021
Q4 		– Hold
0
– – – 2970
2021
Q3 		– Hold
0
– – – 2934
2021
Q2 		– Hold
0
– – – 2910

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

T. Rowe Price Associates's TNXP Position: Q2 2026 in Review

T. Rowe Price Associates increased its Tonix Pharmaceuticals (TNXP) stake by 40% in Q2 2026, buying an estimated $71.6K and bringing the position to 19,363 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #2930.

T. Rowe Price Associates first reported a position in TNXP in Q4 2025 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • T. Rowe Price Associates held 19,363 shares of Tonix Pharmaceuticals worth $248K as of Q2 2026.
  • T. Rowe Price Associates bought 5,547 Tonix Pharmaceuticals shares in Q2 2026, an estimated $71.6K.
  • Tonix Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2930 holding.
  • T. Rowe Price Associates first reported a position in Tonix Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.